Navigation Links
King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide

BRISTOL, Tenn.--(BUSINESS WIRE)--Apr 19, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company's ALTACE(R) (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detail at an upcoming scientific conference.

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the expected presentation of Phase III results for the Company's ALTACE(R) diuretic combination product at an upcoming scientific conference. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors which may cause actual results to differ materially from the forward-looking statements include dependence on King's ability to present the Phase III results for its ALTACE(R) diuretic combination product as planned; and dependence on the final outcome of the Company's review of the data. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in th e "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2006, which is on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

Contact

King Pharmaceuticals, Inc., Bristol
James E. Green, 423-989-8125
Executive Vice President, Corporate Affairs
or
David E. Robinson, 423-989-7045
Senior Director, Corporate Affairs


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... India , March 1, 2017 ... report "Neurovascular Devices/Interventional Neurology Market by Product (Embolic ... Flow Diversion Devices, Clot Retrievers), Pathology (Aneurysm, AVM) ... this report studies the neurovascular devices/interventional neurology market ... The market is expected to reach USD 2.62 ...
(Date:3/1/2017)... Mar 01, 2017 Research and Markets has announced the addition of the ... offering. ... country level, for instance North America (U.S., Canada ... France , Italy , U.K. and Spain ... India , Australia , South Korea ...
(Date:3/1/2017)... -- ... Research and Markets has announced the addition of the ... to their offering. The Global Human Papilloma Virus ... access to partnering deals and agreements entered into by the world,s ... partnering deals. The majority of deals are discovery or development stage ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... Cognition Corporation ... a Human Factors Engineering (HFE) keynote speaker for its 2017 User Conference. , ... Cognition. “Human Factors is a dynamic part of product development, and our speaker ...
(Date:3/1/2017)... IL (PRWEB) , ... March 01, 2017 , ... First ... its latest funding round of $1.6 million. First Stop Health has raised total capital ... accelerate the company’s growth. , First Stop Health co-founder and CEO Patrick Spain (co-founder ...
(Date:3/1/2017)... ... March 01, 2017 , ... One of the most popular shows on ... the beloved character Toby being shocked back to life after suffering cardiac arrest on ... quickly back to his old self, ready to marry his best girl. In ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... the treatment of eating disorders, is pleased to announce the opening of residential ... facility. Starting this week, Aloria Health will accept adult clients for residential treatment. ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... Lung Cancer Conference® on April 8, 2017, in Sunny Isles Beach, Florida. The ... officer, Massachusetts General Physicians Organization, Boston, and Dr. Heather Wakelee, associate professor of ...
Breaking Medicine News(10 mins):